Effects of antidiabetic and antihyperlipidemic agents on C-reactive protein

Mayo Clinic Proceedings

Volumn 83, Issue 3, 2008, Pages 333-342

  Dandona, Paresh ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; ANGIOTENSIN 2 RECEPTOR; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; BIGUANIDE DERIVATIVE; BILE ACID SEQUESTRANT; C REACTIVE PROTEIN; COLESEVELAM; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; GLIMEPIRIDE; GLUCOSE; INSULIN; LIPID; METFORMIN; MEVINOLIN; NICOTINIC ACID; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PRAVASTATIN; ROSIGLITAZONE; SIMVASTATIN; SULFONYLUREA DERIVATIVE;

ARTERY DISEASE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; COMBINATION CHEMOTHERAPY; DISEASE MARKER; DRUG EFFECT; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HEMOSTASIS; HIGH RISK PATIENT; HUMAN; HYPERCOAGULABILITY; HYPERTENSION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; MONOTHERAPY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; RECEPTOR UPREGULATION; REVIEW; RISK FACTOR; STROKE; SUDDEN DEATH; TREATMENT OUTCOME;

EID: 41549090967     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/83.3.333     Document Type: Review

References (105)

1. Granberry MC, Fonseca VA. Cardiovascular risk factors associated with insulin resistance: effects of oral antidiabetic agents. Am J Cardiovasc Drugs. 2005;5(3):201-209.
2. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107(3):499-511.
3. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107(3):363-369.
4. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347(20):1557-1565.
5. Paul A, Ko KW, Li L, et al. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice [published correction appears in Circulation. 2004;109(18):2254]. Circulation. 2004 Feb 10; 109(5):647-655. Epub 2004 Jan 26.
6. Verma S, Wang CH, Li SH, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation. 2002;106(8):913-919.
7. Schulze MB, Rimm EB, Li T, Rifai N, Stampfer MJ, Hu FB. C-reactive protein and incident cardiovascular events among men with diabetes. Diabetes Care. 2004;27(4):889-894.
8. Linnemann B, Voigt W, Nobel W, Janka HU. C-reactive protein is a strong independent predictor of death in type 2 diabetes: association with multiple facets of the metabolic syndrome. Exp Clin Endocrinol Diabetes. 2006;114(3):127-134.
9. Coppola G, Corrado E, Muratori I, et al. Increased levels of C-reactive protein and fibrinogen influence the risk of vascular events in patients with NIDDM. Int J Cardiol. 2006;106(1):16-20.
10. Soinio M, Marniemi J, Laakso M, Lehto S, Ronnemaa T. High-sensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes: a 7-year follow-up study. Diabetes Care. 2006;29(2):329-333.
11. Fritsma G. High sensitivity C-reactive protein. Clin Lab Sci. 2001 Fall;14(4):276-278.
12. Ridker PM, Rifai N, Clearfield M, et al, Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344(26):1959-1965.
13. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350(14):1387-1397.
14. Devaraj S, Du Clos TW, Jialal I. Binding and internalization of C-reactive protein by Fcgamma receptors on human aortic endothelial cells mediates biological effects. Arterioscler Thromb Vasc Biol. 2005 Jul;25(7): 1359-1363. Epub 2005 Apr 28.
15. Griselli M, Herbert J, Hutchinson WL, et al. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med. 1999;190(12):1733-1740.
16. Pepys MB, Hirschfield GM, Tennent GA, et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature. 2006;440(7088): 1217-1221.
17. Pepys MB, Hawkins PN, Kahan MC, et al. Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself. Circ Res. 2005 Nov 25;97(11):e97-e103. Epub 2005 Oct 27.
18. Dasu MR, Devaraj S, Du Clos TW, Jialal I. The biological effects of CRP are not attributable to endotoxin contamination: evidence from TLR4 knockdown human aortic endothelial cells. J Lipid Res. 2007 Mar;48(3):509-512. Epub 2006 Dec 9.
19. Rodriguez-Moran M, Guerrero-Romero F. Elevated concentrations of C-reactive protein in subjects with type 2 diabetes mellitus are moderately influenced by glycemic control. J Endocrinol Invest. 2003;26(3):216-221.
20. Chaudhuri A, Janicke D, Wilson MF, et al. Anti-inflammatory and profibrinolytic effect of insulin in acute ST-segment-elevation myocardial infarction. Circulation. 2004 Feb 24;109(7):849-854. Epub 2004 Feb 2.
21. Visser L, Zuurbier CJ, Hoek FJ, et al. Glucose, insulin and potassium applied as perioperative hyperinsulinaemic normoglycaemic clamp: effects on inflammatory response during coronary artery surgery. Br J Anaesth. 2005 Oct;95(4):448-457. Epub 2005 Aug 12.
22. Koskenkari JK, Kaukoranta PK, Rimpilainen J, et al. Anti-inflammatory effect of high-dose insulin treatment after urgent coronary revascularization surgery. Acta Anaesthesiol Scand. 2006;50(8):962-969.
23. Wong VW, McLean M, Boyages SC, Cheung NW. C-reactive protein levels following acute myocardial infarction: effect of insulin infusion and tight glycemic control. Diabetes Care. 2004;27(12):2971-2973.
24. Takebayashi K, Aso Y, Inukai T. Initiation of insulin therapy reduces serum concentrations of high-sensitivity C-reactive protein in patients with type 2 diabetes. Metabolism. 2004;53(6):693-699.
25. Barrett TD, Hennan JK, Marks RM, Lucchesi BR. C-reactive-protein- associated increase in myocardial infarct size after ischemia/reperfusion. J Pharmacol Exp Ther. 2002;303(3):1007-1013.
26. Valtchanova-Matchouganska A, Gondwe M, Nadar A. The role of C-reactive protein in ischemia/reperfusion injury and preconditioning in a rat model of myocardial infarction. Life Sci. 2004;75(8):901-910.
27. Jonassen AK, Brar BK, Mjos OD, Sack MN, Latchman DS, Yellon DM. Insulin administered at reoxygenation exerts a cardioprotective effect in myocytes by a possible anti-apoptotic mechanism. J Mol Cell Cardiol. 2000;32(5):757-764.
28. Zhang HX, Zang YM, Huo JH, et al. Physiologically tolerable insulin reduces myocardial injury and improves cardiac functional recovery in myocardial ischemic/reperfused dogs. J Cardiovasc Pharmacol. 2006;48(6):306-313.
29. Aljada A, Ghanim H, Saadeh R, Dandona P. Insulin inhibits NFkappaB and MCP-1 expression in human aortic endothelial cells. J Clin Endocrinol Metab. 2001;86(1):450-453.
30. Aljada A, Saadeh R, Assian E, Ghanim H, Dandona P. Insulin inhibits the expression of intercellular adhesion molecule-1 by human aortic endothelial cells through stimulation of nitric oxide. J Clin Endocrinol Metab. 2000; 85(7):2572-2575.
31. Bisgaard T, Klarskov B, Kehlet H, Rosenberg J. Preoperative dexamethasone improves surgical outcome after laparoscopic cholecystectomy: a randomized double-blind placebo-controlled trial. Ann Surg. 2003;238(5):651-660.
32. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) [published correction appears in Lancet. 1998;352(9139):1558]. Lancet. 1998;352(9131):854-865.
33. Chu NV, Kong AP, Kim DD, et al. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes [published correction appears in Diabetes Care. 2002;25(5):947]. Diabetes Care. 2002;25(3):542-549.
34. Carter AM, Bennett CE, Bostock JA, Grant PJ. Metformin reduces C-reactive protein but not complement factor C3 in overweight patients with Type 2 diabetes mellitus. Diabet Med. 2005;22(9):1282-1284.
35. Caballero AE, Delgado A, Aguilar-Salinas CA, et al. The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab. 2004;89(8):3943-3948.
36. Dandona P, Aljada A, Ghanim H, et al. Increased plasma concentration of macrophage migration inhibitory factor (MIF) and MIF mRNA in mononuclear cells in the obese and the suppressive action of metformin. J Clin Endocrinol Metab. 2004;89(10):5043-5047.
37. Aljada A, Garg R, Ghanim H, et al. Nuclear factor-κB suppressive and inhibitor-κB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action? J Clin Endocrinol Metab. 2001;86(7):3250-3256.
38. Ghanim H, Garg R, Aljada A, et al. Suppression of nuclear factor-κB and stimulation of inhibitor κB by troglitazone: evidence for an antiinflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab. 2001;86(3):1306-1312.
39. Tan SA, Tan LG, Berk LS. Comparative study of the effects of rosiglitazone and pioglitazone on interferon-γ, tumour necrosis factor, interleukin-1β, interleukin-4, interleukin-6 and C-reactive protein in diabetic patients with atherosclerosis. Diabetes. 2002;51(suppl 2):A595.
40. Brunzell JD, Marcovina S, Yu D, et al. Rosiglitazone reduces novel biomarkers of cardiovascular disease in subjects with type 2 diabetes mellitus already on statin therapy [abstract 1124-192]. J Am Coll Cardiol. 2004; 43(5)(suppl 2):504A.
41. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 2002;106(6): 679-684.
42. Medlej RC, Gannage MHE, Halaby GH. Effects of rosiglitazone on insulin resistance, CRP and adiponectin levels in Lebanese type 2 diabetics: a preliminary study. Diabetes. 2005;54(suppl 1):510.
43. Mohanty P, Aljada A, Ghanim H, et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab. 2004; 89(6):2728-2735.
44. Sarafidis PA, Lasaridis AN, Nilsson PM, et al. The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension: an open-label observational study. Metabolism. 2005;54(9):1236-1242.
45. Satoh N, Ogawa Y, Usui T, et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care. 2003;26(9):2493-2499.
46. Pfutzner A, Marx N, Lubben G, et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol. 2005;45(12):1925-1931.
47. Derosa G, Fogari E, Cicero AF, et al. Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. Hypertens Res. 2007;30(5):387-394.
48. Mattoo V, Eckland D, Widel M, et al. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study. Clin Ther. 2005;27(5):554-567.
49. Takase H, Nakazawa A, Yamashita S, et al. Pioglitazone produces rapid and persistent reduction of vascular inflammation in patients with hypertension and type 2 diabetes mellitus who are receiving angiotensin II receptor blockers. Metabolism. 2007;56(4):559-564.
50. Dormandy JA, Charbonnel B, Eckland DJ, et al, PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro-Vascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279-1289.
51. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes [published correction appears in N Engl J Med. 2007;357(1):100]. N Engl J Med. 2007 Jun 14;356(24):2457-2471. Epub 2007 May 21.
52. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007;298(10):1189-1195.
53. Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care. 2007 Aug;30(8):2148-2153. Epub 2007 May 29.
54. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298(10):1180-1188.
55. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112(12):1796-1808.
56. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391(6662):82-86.
57. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med. 2001;7(1):48-52.
58. Alleva DG, Johnson EB, Lio FM, Boehme SA, Conlon PJ, Crowe PD. Regulation of murine macrophage proinflammatory and anti-inflammatory cytokines by ligands for peroxisome proliferator-activated receptor-gamma: counter-regulatory activity by IFN-gamma. J Leukoc Biol. 2002;71(4):677-685.
59. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 1998;391(6662):79-82.
60. Verma S, Kuliszewski MA, Li SH, et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation. 2004 May 4;109(17):2058-2067. Epub 2004 Apr 12.
61. Ghanim H, Dhindsa S, Aljada A, Chaudhuri A, Viswanathan P, Dandona P. Low-dose rosiglitazone exerts an antiinflammatory effect with an increase in adiponectin independently of free fatty acid fall and insulin sensitization in obese type 2 diabetics. J Clin Endocrinol Metab. 2006 Sep; 91(9):3553-3558. Epub 2006 Jun 27.
62. Akbar DH. Effect of metformin and sulfonylurea on C-reactive protein level in well-controlled type 2 diabetics with metabolic syndrome. Endocrine. 2003;20(3):215-218.
63. Yudkin JS, Panahloo A, Stehouwer C, et al. The influence of improved glycaemic control with insulin and sulphonylureas on acute phase and endothelial markers in type II diabetic subjects. Diabetologia. 2000;43(9): 1099-1106.
64. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998; 339(4):229-234.
65. Garg A, Grundy SM. Management of dyslipidemia in NIDDM. Diabetes Care. 1990;13(2):153-169.
66. Gotto AM Jr. Triglyceride as a risk factor for coronary artery disease. Am J Cardiol. 1998;82(9A):22Q-25Q.
67. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 1998;98(9):839-844.
68. Albert MA, Danielson E, Rifai N, Ridker PM, PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/ CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286(1):64-70.
69. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation. 2001;103(15):1933-1935.
70. Nissen SE, Tuzcu EM, Schoenhagen P, et al, REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291(9):1071-1080.
71. Ridker PM, Morrow DA, Rose LM, Rifai N, Cannon CP, Braunwald E. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dL and C-reactive protein <2 mg/L: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol. 2005 May 17;45(10):1644-1648. Epub 2005 Apr 25.
72. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E, Cholesterol and Recurrent Events (CARE) Investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation.1999;100(3):230- 235.
73. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation. 2002;106(16):2055-2060.
74. van de Ree MA, Huisman MV, Princen HM, Meinders AE, Kluft C, DALI Study Group. Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis. 2003;166(1):129-135.
75. van Wissen S, Trip MD, Smilde TJ, de Graaf J, Stalenhoef AF, Kastelein JJ. Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy. Atherosclerosis. 2002; 165(2):361-366.
76. Ridker PM, JUPITER Study Group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation. 2003;108(19):2292-2297.
77. Arnaud C, Burger F, Steffens S, et al. Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins. Arterioscler Thromb Vasc Biol. 2005 Jun;25(6):1231-1236. Epub 2005 Mar 24.
78. Grundy SM, Vega GL, McGovern ME, et al, Diabetes Multicenter Research Group. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med. 2002;162(14):1568-1576.
79. Kashyap ML, McGovern ME, Berra K, et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol. 2002;89(6):672-678.
80. Keating GM, Ormrod D. Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia. Drugs. 2002;62(13): 1909-1944.
81. Keech A, Simes RJ, Barter P, et al, FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial [published corrections appear in Lancet. 2006;368(9545):1415 and 2006;368(9545): 1420]. Lancet. 2005;366(9500):1849-1861.
82. Zambon A, Gervois P, Pauletto P, Fruchart JC, Staels B. Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-α activators: clinical and experimental evidence. Arterioscler Thromb Vasc Biol. 2006 May;26(5):977-986. Epub 2006 Jan 19.
83. Staels B, Koenig W, Habib A, et al. Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators. Nature. 1998;393(6687):790-793.
84. Malik J, Melenovsky V, Wichterle D, et al. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial - FAT). Cardiovasc Res. 2001;52(2):290-298.
85. Rizos E, Kostoula A, Elisaf M, Mikhailidis DP. Effect of ciprofibrate on C-reactive protein and fibrinogen levels. Angiology. 2002;53(3):273-277.
86. Despres JP, Lemieux I, Pascot A, et al. Gemfibrozil reduces plasma C-reactive protein levels in abdominally obese men with the atherogenic dyslipidemia of the metabolic syndrome [letter]. Arterioscler Thromb Vasc Biol. 2003;23(4):702-703.
87. Wang TD, Chen WJ, Lin JW, Cheng CC, Chen MF, Lee YT. Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles. Atherosclerosis. 2003;170(2):315-323.
88. Farnier M, Freeman MW, Macdonell G, et al, Ezetimibe Study Group. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur Heart J. 2005 May;26(9):897-905. Epub 2005 Mar 21.
89. Okopien B, Krysiak R, Herman ZS. Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance. J Clin Endocrinol Metab. 2006 May;91(5): 1770-1778. Epub 2006 Feb 21.
90. Delerive P, Gervois P, Fruchart JC, Staels B. Induction of IκBα expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J Biol Chem. 2000; 275(47):36703-36707.
91. Bays H, Dujovne C. Colesevelam HCl: a non-systemic lipid-altering drug. Expert Opin Pharmacother. 2003;4(5):779-790.
92. Brensike JF, Levy RI, Kelsey SF, et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation. 1984;69(2):313-324.
93. Davidson MH, Dillon MA, Gordon B, et al. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med. 1999;159(16):1893-1900.
94. Insull W Jr, Toth P, Mullican W, et al. Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. Mayo Clin Proc. 2001;76(10):971-982.
95. Bays HE, Rhyne J, Abby S, Lai Y-L, Jones MR. Lipid lowering effects of colesevelam HCl in combination with ezetimibe [abstract P82]. Arterioscler Thromb Vasc Biol. 2006;26(5):e67.
96. Insull W Jr. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med J. 2006;99(3):257-273.
97. Bays HE, Davidson M, Jones MR, Abby SL. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity Creactive protein when added to statins in patients with hypercholesterolemia [published correction appears in Am J Cardiol. 2006;98(3):428]. Am J Cardiol. 2006 Apr 15;97(8):1198-1205. Epub 2006 Mar 3.
98. Devaraj S, Autret B, Jialal I. Effects of colesevelam hydrochloride (WelChol) on biomarkers of inflammation in patients with mild hypercholesterolemia. Am J Cardiol. 2006 Sep 1;98(5):641-643. Epub 2006 Jul 7.
99. Zieve FJ, Kalin MF, Schwartz SL, Jones MR, Bailey WL. Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther. 2007;29(1):74-83.
100. Goldberg RB, Truitt K. Colesevelam HCl improves glycemic control in type 2 diabetes mellitus subjects managed with insulin therapy. Paper presented at: American Heart Association 2006 Annual Meeting; Chicago, IL; November 12-15, 2006. Poster Presentation No. 1581.
101. Bays H, Goldberg RB, Truitt K, Dmuchowski C, Jones M. Addition of colesevelam HCl to metformin (MET)-based therapy in patients with inadequately controlled type 2 diabetes mellitus improves glycemic control [abstract 204]. In: Abstracts of the American Association of Clinical Endocrinologists 16th Annual Meeting and Clinical Congress; Seattle, WA; April 11-15, 2007:18-19.
102. Fonseca VA, Rosenstock J, Truitt K, Dmuchowski C, Jones M. Colesevelam HCl added to sulfonylurea (SU)-based therapy in patients with inadequately controlled type 2 diabetes mellitus (T2DM) improves glycemic control [abstract 409].In: Abstracts of the American Association of Clinical Endocrinologists 16th Annual Meeting and Clinical Congress; Seattle, WA; April 11-15, 2007:10-11.
103. Sager PT, Capece R, Lipka L, et al. Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. Atherosclerosis. 2005 Apr;179(2):361-367. Epub 2004 Dec 15.
104. Bays HE, Ose L, Fraser N, et al, Ezetimibe Study Group. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/ simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther. 2004;26(11):1758-1773.
105. Sager PT, Melani L, Lipka L, et al, Ezetimibe Study Group. Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am J Cardiol. 2003;92(12):1414-1418.